Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

Chuikyo General Assembly Meeting on Dec. 20 Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a suite of measures aimed at driving innovation and stemming the growing trends of...read more